Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - NETs and endocrine tumours

1156 - Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: the FFCD 1104-EVACEL-GTE phase II study

Date

22 Oct 2018

Session

Poster Discussion session - NETs and endocrine tumours

Presenters

Thomas Walter

Citation

Annals of Oncology (2018) 29 (suppl_8): viii467-viii478. 10.1093/annonc/mdy293

Authors

T. Walter1, C. Lepage2, R. Coriat3, E. Barbier4, G. Cadiot5, F.X. Caroli Bosc6, T. Aparicio7, K. Bouhier Leporrier8, O. Hentic Dhome9, A. Dupont-Gossart10, M. Duluc11, C. Lepere12, T. Lecomte13, D. Smith14, C. Petorin15, I. Iwanicki Caron16, M.P. Ducreux17, C. Lombard Bohas18, T. de Baere19

Author affiliations

  • 1 Gastroenterology And Medical Oncology Department, CHU Edouard Herriot, 69437 - LYON/FR
  • 2 Hepatogastroenterology And Digestive Oncology Department, University hospital Dijon, University of Burgundy and Franche Comté, FFCD, EPICAD INSERM LNC-UMR 1231, 21079 - Dijon/FR
  • 3 Gastroenterology Department, Cochin Hospital, 75014 - Paris/FR
  • 4 Biostatistics, FFCD, EPICAD INSERM LNC-UMR 1231,, University of Burgundy and Franche Comté, 21079 - Dijon/FR
  • 5 Gastroenterology Department, CHU Robert Debré, 51092 - Reims/FR
  • 6 Gastroenterology Department, CHU Angers, 49933 - Angers/FR
  • 7 Gastroenterology Department, Saint Louis Hospital AP-HP, 75010 - Paris/FR
  • 8 Gastroenterology Department, CHU Côte de Nacre, 14033 - Caen/FR
  • 9 Gastroenterology Department, Beaujon Hospital, 92110 - Clichy/FR
  • 10 Gastroenterology Department, Jean Minjoz Hospital, 25030 - Besançon/FR
  • 11 Gastroenterology Department, CHU La Timone, 13385 - Marseille/FR
  • 12 Gastroenterology Department, European Georges Pompidou Hospital, 75015 - Paris/FR
  • 13 Gastroenterology Department, CHU Tours, 37170 - Tours/FR
  • 14 Digestive Oncology Department, CHU Haut Lévêque, 33000 - Bordeaux/FR
  • 15 Digestive Oncology Department, CHU Estaing, 63003 - Clermont-Ferrand/FR
  • 16 Gastroenterology Department, CHU Charles Nicolle, 76031 - Rouen/FR
  • 17 Medical Oncology Department, Gustave Roussy, Paris Saclay University, 94805 - Villejuif/FR
  • 18 Oncology Department, Edouard Herriot Hospital, Cancer Institute Hospices Civils de Lyon, 69437 - Lyon/FR
  • 19 Interventional Radiology Department, Gustave Roussy Villejuif & UFR Medecine Kremlin Biceter Paris Sud University, 94805 - Villejuif/FR
More

Resources

Abstract 1156

Background

Transarterial liver therapy (TALT) is indicated in the treatment of isolated or predominant progressive liver metastases of gastrointestinal neuroendocrine tumors (GI-NETs). TALT increases circulating VEGF levels. Everolimus is an approved systemic treatment in NETs that has anti-angiogenic activities. Our hypothesis is that everolimus may increase hepatic progression-free survival (hPFS) 24 months after TALT.

Methods

EVACEL is a single arm phase II multicenter prospective study conducted in patients with predominant and progressive liver metastases within previous 12 months from well-differentiated grade 1-2 GI-NETs. Everolimus (10 mg/day) was started 7 days after TALT, once liver toxicity was grade ≤1. The primary endpoint was the hPFS rate at 24 months (≥35% is sufficient to demonstrate efficacy, 50% is expected) based on the central review assessment.

Results

The characteristics of the 77 enrolled patients were female 42%, median age 66 (range: 43-86) years, primary tumor in the small bowel 91%, grade G1 43%, G2 57%, extra-hepatic metastases 51%), median liver tumor burden 30% (range, 1-80), and previous somatostatin analog treatment 74%. Patients underwent 1 (n = 19), 2 (n = 54) or 3 (n = 1) TALT: bland (n = 21) or chemo-embolization (n = 109). Sixty-seven (87%) pts were eligible for everolimus. Forty (54%) and 30 (41%) pts had objective response (RECIST 1.1) and stable disease, respectively (1 pt was not evaluable). Median (IC 95%) PFS and overall survival were 16.9 (12.6-22.3) and 44.6 (29.1-not reached) months, respectively. The most common grade 3-4 toxicities (>5%) in patients receiving both TALT and everolimus (n = 67) were the post-TALT syndrome (55%), fatigue (18%), diarrhea (16%), anemia (12%), cutaneous (9%), hypertriglyceridemia (7.5%) and mucositis (6%). The primary endpoint will be presented at the meeting.

Conclusions

Everolimus can be safely administered following TALT. Results of this sequence of therapies are encouraging.

Clinical trial identification

NCT01678664.

Legal entity responsible for the study

FFCD.

Funding

FFCD.

Editorial Acknowledgement

Novartis Pharma AG provided an unrestricted research grant.

Disclosure

T. Walter: Congress, advisory board, research: Novartis, Ipsen, Keocyt, AAA. C. Lepage: Research: Ipsen Pharma, Novartis Oncology; Speaker: Advanced Accelerator Applications; Travel, accomodations: Amgen, Ipsen Pharma, Novartis Oncology, Bayer. R. Coriat: Consulting or advisory role: Keocyt, Pfizer, Novartis, Roche, Merck, Amgen, Bayer; Research funding: Amgen, Novartis, Ipsen; Travel, accomodations, expenses: Ipsen, Amgen, Bayer. G. Cadiot: Honoraria: Ipsen, Novartis, Pfizer, AAA, Keocyt; Consulting or advisory role: Ipsen, Novartis, Pfizer, AAA, Keocyt; Research funding: Ipsen, Novartis. F.X. Caroli Bosc: Honoraria: Ipsen, Novartis, Lilly, Amgen. T. Aparicio: Honoraria: Shire, Roche, Servier, BMS, Amgen, Léo Pharma; Consulting or advisory role: BMS, Halio DX; Research funding: Novartis; Travel, accomodations, expenses: Roche, Hospira, Ipsen. K. Bouhier Leporrier: Honoraria, boards and congress: Ipsen and Novartis. C. Lepere: Consulting or advisory role: Novartis, Ipsen; Travel, accomodations, expenses: Ipsen, Novartis, Amgen. T. Lecomte: Consulting or advisory role, research funding, travel: Novartis; Consulting or advisory role, Travel: Ipsen. D. Smith: Speaker’s bureau: Novartis; Consulting or advisory role: Novartis, Pfizer. C. Petorin: Travel, accomodations, expenses: Novartis. M.P. Ducreux: Grants/research supports: Roche, Chugai, Pfizer; Honoraria or consultation fees: Roche, Celgene, Merck Serono, Amgen, Novartis, Sanofi, Pfizer, Lilly, Servier; Spouse: Head of BU, Sandoz. C. Lombard Bohas: Consulting or advisory role: Ipsen, Novartis, Pfizer, Advanced Accelerator Applications. T. de Baere: Consulting or advisory role, speaker’s bureau: Guerbet. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings